New York, March 1, 2026, 11:19 EST — Market closed.
- Eli Lilly shares rose 2.93% on Friday to $1,051.99, snapping a three-session slide.
- A European medicines panel backed broader use of Lilly’s Olumiant for severe alopecia areata in adolescents.
- Investors now look to a March 2 conference appearance for any fresh read on pricing, supply and the pipeline.
Eli Lilly and Co shares ended Friday up 2.9% at $1,051.99, outperforming a weak broader tape as investors weighed a new European regulatory step for one of the drugmaker’s immunology franchises. 1
The move matters because Lilly’s stock has become a crowded trade built on years of growth assumptions, and the market has started to reward incremental proof that the company can keep widening its set of catalysts beyond its marquee metabolic drugs.
With U.S. markets shut for the weekend, traders will be watching whether Monday brings fresh positioning around healthcare and any new signals on how quickly payers and rivals are pressing on price.
The European Medicines Agency said its Committee for Medicinal Products for Human Use (CHMP) backed a change that would allow baricitinib — sold as Olumiant — to treat severe alopecia areata in adults and adolescents aged 12 and over in the European Union. (Alopecia areata is an immune disease that can cause substantial hair loss.) 2
Lilly and partner Incyte said Phase 3 BRAVE-AA-PEDS data showed 42.4% of adolescents on the 4 mg dose reached at least 80% scalp hair coverage at 36 weeks. Lilly executive Anabela Cardoso said the opinion “supports the potential expansion of Olumiant”; dermatologist Thierry Passeron said families “are frequently left with limited options that fall short.” Lilly said a European Commission decision is expected in the next one to two months. 3
On Friday, the stock’s rise came as the S&P 500 and the Dow closed lower, and trading volume in Lilly was above its recent average. The shares also remained below their January high. 4
Investors have leaned on Lilly’s guidance and demand for its diabetes and obesity medicines to justify a premium valuation, with the company flagging strong 2026 growth driven by its metabolic franchise. 5
That story still carries a pricing question mark. Rival Novo Nordisk has said it will cut U.S. list prices on Ozempic and Wegovy from 2027, a move that has kept “price war” chatter alive around GLP-1 drugs even as demand stays strong. 6
But Olumiant sits in a drug class that has faced intense scrutiny. The U.S. label carries a boxed warning — the FDA’s strongest caution — for risks including serious infections, malignancy, major adverse cardiovascular events and thrombosis, which can curb uptake and widen the downside if regulators or doctors turn more cautious. 7
Next up, Lilly’s chief financial officer Lucas Montarce is scheduled to speak in a fireside chat at TD Cowen’s annual health care conference on Monday, March 2, at 3:10 p.m. Eastern — a near-term checkpoint for any updated tone on supply, pricing and the pipeline cadence. 8
